DOCSLIB.ORG

Anti-Dock6 Code No

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anti-Dock6 Code No PD016 For Research Use Only. Page 1 of 2 Not for use in diagnostic procedures. POLYCLONAL ANTIBODY Anti-Dock6 Code No. Quantity Form PD016 100 L Affinity Purified BACKGROUND: Small GTPases of the Rho family, SPECIES CROSS REACTIVITY: Rho, Rac, and Cdc42, are essential regulators of the Species Human Mouse Rat dynamics of actin cytoskeletal structures and diverse cellular events requiring the actin cytoskeleton. Signaling Cells 293T N1E-115 PC12 specificity of Rho GTPase pathways is achieved in part by Reactivity on WB + + + selective interaction between members of the Dbl family guanine nucleotide exchange factors (GEFs) and their Rho GTPase substrates. Dock180, also known as dedicator of INTENDED USE: cytokinesis 1 (Dock1), is an atypical GEFs for the Rho For Research Use Only. Not for use in diagnostic procedures. GTPases. It has been revealed an evolutionarily conserved protein superfamily with homology to Dock180 comprised REFERENCES: of at least 11 mammalian members. This family is 1) Miyamoto, Y., et al., Exp. Cell Res. 313, 791-804 (2007) structurally divided into four classes Dock-A, -B, -C, and 2) Côté, J. F., and Vuori, K., J. Cell Sci. 115, 4901-4913 (2002) -D. Dock6 belongs to the Dock-C subfamily, displays GEF activities for both Rac1 and Cdc42 and may be one of This antibody is used in reference number 1). physiological regulators of neurite outgrowth. On the other hand, member of the Dock-A and -B subfamilies except for Dock4 are Rac1-specific GEFs. Dock9 of the Dock-D 1 2 3 4 5 subfamily has specificity for Cdc42. kDa 220 - SOURCE: This antibody was purified from rabbit serum 170 - using affinity column. The rabbit was immunized with the mouse Dock6 synthetic peptide PHSLNFSSRQGSV (553-565 aa). 116 - FORMULATION: 100 L volume of PBS containing 50% glycerol, pH 7.2. No preservative is contained. 76 - STORAGE: This antibody solution is stable for one year from the date of purchase when stored at -20oC. 53 - REACTIVITY: This antibody reacts with Dock6 on Western blotting. Western blot analysis of Dock6 expression in 293T (1), N1E-115 APPLICATIONS: (2), PC12 (3), mock transfectant (4) Western blotting; 1:100-1:300 for chemiluminescence and human Dock6 transfectant (5) detection system using PD016. Immunoprecipitation; Not tested Immunohistochemistry; Not tested Immunocytochemistry; Not tested* *It is reported that this polyclonal antibody can be used PROTOCOL: in Immunocytochemistry in the reference number 1). SDS-PAGE & Western Blotting Flow cytometry; Not tested 1) Subconfluent cultured cells are grown in 100-mm dishes. 2) Wash the cells 3 times with PBS. Add 400 L of Detailed procedure is provided in the following Laemmli’s sample buffer to the dish and scrape the cells PROTOCOL. into microcentrifuge tubes. 3) Boil the samples for 5 minutes and sonicate briefly (up to 10 seconds). Centrifuge the tube at 12,000 x g for 5 minutes at 4oC. MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. URL https://ruo.mbl.co.jp e-mail [email protected], TEL 052-238-1904 PD016 Page 2 of 2 4) Load 20 L of the sample per lane in a 1 mm thick SDS-polyacrylamide gel for electrophoresis. 5) Blot the protein to a polyvinylidene difluoride (PVDF) membrane at 1 mA/cm2 for 1 hour in a semi-dry transfer system (Transfer Buffer: 25 mM Tris, 190 mM glycine, 20% MeOH). See the manufacture's manual for precise transfer procedure. 6) To reduce nonspecific binding, place the membrane in blocking buffer (10% skimmed milk, 100 mM Tri-HCl, pH 7.6, 154 mM NaCl, 0.05% Tween-20) overnight at 4oC. 7) Incubate the membrane with primary antibody diluted with blocking buffer as suggest in the APPLICATIONS for 1 hour at room temperature. (The concentration of antibody will depend on condition.) 8) Wash the membrane with PBS-T [0.05% Tween-20 in PBS] (5 minutes x 3 times). 9) Incubate the membrane with the 1:10,000 HRP-conjugated anti-rabbit IgG (MBL; code no. 458) diluted with 1% skimmed milk (in PBS, pH 7.2) for 1 hour at room temperature. 10) Wash the membrane with PBS-T (10 minutes x 3 times). 11) Wipe excess buffer on the membrane, then incubate it with appropriate chemiluminescence reagent for 1 minute. 12) Remove extra reagent from the membrane by dabbing with paper towel, and seal it in plastic wrap. 13) Expose to an X-ray film in a dark room for 3 minutes. 14) Develop the film as usual. The condition for exposure and development may vary. (Positive controls for Western blotting; 293T, N1E-115, PC12) 071009-1.1 .
Load more

Recommended publications
  • NICU Gene List Generator.Xlsx
    Neonatal Crisis Sequencing Panel Gene List Genes: A2ML1 - B3GLCT A2ML1 ADAMTS9 ALG1 ARHGEF15 AAAS ADAMTSL2 ALG11 ARHGEF9 AARS1 ADAR ALG12 ARID1A AARS2 ADARB1 ALG13 ARID1B ABAT ADCY6 ALG14 ARID2 ABCA12 ADD3 ALG2 ARL13B ABCA3 ADGRG1 ALG3 ARL6 ABCA4 ADGRV1 ALG6 ARMC9 ABCB11 ADK ALG8 ARPC1B ABCB4 ADNP ALG9 ARSA ABCC6 ADPRS ALK ARSL ABCC8 ADSL ALMS1 ARX ABCC9 AEBP1 ALOX12B ASAH1 ABCD1 AFF3 ALOXE3 ASCC1 ABCD3 AFF4 ALPK3 ASH1L ABCD4 AFG3L2 ALPL ASL ABHD5 AGA ALS2 ASNS ACAD8 AGK ALX3 ASPA ACAD9 AGL ALX4 ASPM ACADM AGPS AMELX ASS1 ACADS AGRN AMER1 ASXL1 ACADSB AGT AMH ASXL3 ACADVL AGTPBP1 AMHR2 ATAD1 ACAN AGTR1 AMN ATL1 ACAT1 AGXT AMPD2 ATM ACE AHCY AMT ATP1A1 ACO2 AHDC1 ANK1 ATP1A2 ACOX1 AHI1 ANK2 ATP1A3 ACP5 AIFM1 ANKH ATP2A1 ACSF3 AIMP1 ANKLE2 ATP5F1A ACTA1 AIMP2 ANKRD11 ATP5F1D ACTA2 AIRE ANKRD26 ATP5F1E ACTB AKAP9 ANTXR2 ATP6V0A2 ACTC1 AKR1D1 AP1S2 ATP6V1B1 ACTG1 AKT2 AP2S1 ATP7A ACTG2 AKT3 AP3B1 ATP8A2 ACTL6B ALAS2 AP3B2 ATP8B1 ACTN1 ALB AP4B1 ATPAF2 ACTN2 ALDH18A1 AP4M1 ATR ACTN4 ALDH1A3 AP4S1 ATRX ACVR1 ALDH3A2 APC AUH ACVRL1 ALDH4A1 APTX AVPR2 ACY1 ALDH5A1 AR B3GALNT2 ADA ALDH6A1 ARFGEF2 B3GALT6 ADAMTS13 ALDH7A1 ARG1 B3GAT3 ADAMTS2 ALDOB ARHGAP31 B3GLCT Updated: 03/15/2021; v.3.6 1 Neonatal Crisis Sequencing Panel Gene List Genes: B4GALT1 - COL11A2 B4GALT1 C1QBP CD3G CHKB B4GALT7 C3 CD40LG CHMP1A B4GAT1 CA2 CD59 CHRNA1 B9D1 CA5A CD70 CHRNB1 B9D2 CACNA1A CD96 CHRND BAAT CACNA1C CDAN1 CHRNE BBIP1 CACNA1D CDC42 CHRNG BBS1 CACNA1E CDH1 CHST14 BBS10 CACNA1F CDH2 CHST3 BBS12 CACNA1G CDK10 CHUK BBS2 CACNA2D2 CDK13 CILK1 BBS4 CACNB2 CDK5RAP2
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • Strand Breaks for P53 Exon 6 and 8 Among Different Time Course of Folate Depletion Or Repletion in the Rectosigmoid Mucosa
    SUPPLEMENTAL FIGURE COLON p53 EXONIC STRAND BREAKS DURING FOLATE DEPLETION-REPLETION INTERVENTION Supplemental Figure Legend Strand breaks for p53 exon 6 and 8 among different time course of folate depletion or repletion in the rectosigmoid mucosa. The input of DNA was controlled by GAPDH. The data is shown as ΔCt after normalized to GAPDH. The higher ΔCt the more strand breaks. The P value is shown in the figure. SUPPLEMENT S1 Genes that were significantly UPREGULATED after folate intervention (by unadjusted paired t-test), list is sorted by P value Gene Symbol Nucleotide P VALUE Description OLFM4 NM_006418 0.0000 Homo sapiens differentially expressed in hematopoietic lineages (GW112) mRNA. FMR1NB NM_152578 0.0000 Homo sapiens hypothetical protein FLJ25736 (FLJ25736) mRNA. IFI6 NM_002038 0.0001 Homo sapiens interferon alpha-inducible protein (clone IFI-6-16) (G1P3) transcript variant 1 mRNA. Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15 GALNTL5 NM_145292 0.0001 (GALNT15) mRNA. STIM2 NM_020860 0.0001 Homo sapiens stromal interaction molecule 2 (STIM2) mRNA. ZNF645 NM_152577 0.0002 Homo sapiens hypothetical protein FLJ25735 (FLJ25735) mRNA. ATP12A NM_001676 0.0002 Homo sapiens ATPase H+/K+ transporting nongastric alpha polypeptide (ATP12A) mRNA. U1SNRNPBP NM_007020 0.0003 Homo sapiens U1-snRNP binding protein homolog (U1SNRNPBP) transcript variant 1 mRNA. RNF125 NM_017831 0.0004 Homo sapiens ring finger protein 125 (RNF125) mRNA. FMNL1 NM_005892 0.0004 Homo sapiens formin-like (FMNL) mRNA. ISG15 NM_005101 0.0005 Homo sapiens interferon alpha-inducible protein (clone IFI-15K) (G1P2) mRNA. SLC6A14 NM_007231 0.0005 Homo sapiens solute carrier family 6 (neurotransmitter transporter) member 14 (SLC6A14) mRNA.
    [Show full text]
  • Small Gtpases of the Ras and Rho Families Switch On/Off Signaling
    International Journal of Molecular Sciences Review Small GTPases of the Ras and Rho Families Switch on/off Signaling Pathways in Neurodegenerative Diseases Alazne Arrazola Sastre 1,2, Miriam Luque Montoro 1, Patricia Gálvez-Martín 3,4 , Hadriano M Lacerda 5, Alejandro Lucia 6,7, Francisco Llavero 1,6,* and José Luis Zugaza 1,2,8,* 1 Achucarro Basque Center for Neuroscience, Science Park of the Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), 48940 Leioa, Spain; [email protected] (A.A.S.); [email protected] (M.L.M.) 2 Department of Genetics, Physical Anthropology, and Animal Physiology, Faculty of Science and Technology, UPV/EHU, 48940 Leioa, Spain 3 Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, 180041 Granada, Spain; [email protected] 4 R&D Human Health, Bioibérica S.A.U., 08950 Barcelona, Spain 5 Three R Labs, Science Park of the UPV/EHU, 48940 Leioa, Spain; [email protected] 6 Faculty of Sport Science, European University of Madrid, 28670 Madrid, Spain; [email protected] 7 Research Institute of the Hospital 12 de Octubre (i+12), 28041 Madrid, Spain 8 IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain * Correspondence: [email protected] (F.L.); [email protected] (J.L.Z.) Received: 25 July 2020; Accepted: 29 August 2020; Published: 31 August 2020 Abstract: Small guanosine triphosphatases (GTPases) of the Ras superfamily are key regulators of many key cellular events such as proliferation, differentiation, cell cycle regulation, migration, or apoptosis. To control these biological responses, GTPases activity is regulated by guanine nucleotide exchange factors (GEFs), GTPase activating proteins (GAPs), and in some small GTPases also guanine nucleotide dissociation inhibitors (GDIs).
    [Show full text]
  • Signature Redacted Author
    Automated, highly scalable RNA-seq analysis ARCHNES M ASSA HUSETS INS ITUTE by Rory Kirchner RSEP 24 2015 B.S., Rochester Institute of Technology (1999) LIBRARIES Submitted to the Department of Health Sciences and Technology in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Health Sciences and Technology at the MASSACHUSETTS INSTITUTE OF TECHNOLOGY September 2015 D Massachusetts Institute of Technology 2015. All rights reserved. Signature redacted Author. Department of Health S ences and Technology Septem 2015 Signature redacted Certified by... Martha Constantine-Paton Professor of E rain and Cognitive Science Thesis Supervisor Signature redacted Acrented by ...... ........ Emery N. Brown Director, Harvard- Program in Health Sciences and Technology Professor of Computational Neuroscience and Health Sciences and Technology F Automated, highly scalable RNA-seq analysis by Rory Kirchner Submitted to the Department of Health Sciences and Technology on September 1, 2015, in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Health Sciences and Technology Abstract RNA-sequencing is a sensitive method for inferring gene expression and provides ad- ditional information regarding splice variants, polymorphisms and novel genes and isoforms. Using this extra information greatly increases the complexity of an analysis and prevents novice investigators from analyzing their own data. The first chapter of this work introduces a solution to this issue. It describes a community-curated, scal- able RNA-seq analysis framework for performing differential transcriptome expres- sion, transcriptome assembly, variant and RNA-editing calling. It handles the entire stack of an analysis, from downloading and installing hundreds of tools, libraries and genomes to running an analysis that is able to be scaled to handle thousands of samples simultaneously.
    [Show full text]
  • Structure Based Drug Design of High Affinity Kras Inhibitors
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 5-2018 STRUCTURE BASED DRUG DESIGN OF HIGH AFFINITY KRAS INHIBITORS Michael McCarthy Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Medicinal Chemistry and Pharmaceutics Commons, Medicine and Health Sciences Commons, and the Pharmacology Commons Recommended Citation McCarthy, Michael, "STRUCTURE BASED DRUG DESIGN OF HIGH AFFINITY KRAS INHIBITORS" (2018). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 829. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/829 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. STRUCTURE BASED DRUG DESIGN OF HIGH AFFINITY KRAS INHIBITORS by Michael McCarthy, B.S., M.S. APPROVED: ______________________________ Alemayehu A. Gorfe, Ph.D. Advisory Professor ______________________________ John F. Hancock, M.B., B.Chir., Ph.D. ______________________________ John A. Putkey, Ph.D. ______________________________ Shane R. Cunha, Ph.D. ______________________________ Jeffrey T. Chang, Ph.D. APPROVED: ______________________________ Dean, The University of Texas Graduate School of Biomedical Sciences at Houston STRUCTURE BASED DRUG DESIGN OF HIGH AFFINITY KRAS INHIBITORS A DISSERTATION Presented to the Faculty of The University of Texas M.
    [Show full text]
  • Yeshavanth Kumar Banasavadi
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 13 May 2021 doi:10.20944/preprints202105.0285.v1 Review of PP2A tumor biology and anti-tumor effects of PP2A inhibitor LB100 in the nervous system Authors: Jean-Paul Bryant, MSc,1 Adam Levy, BS,2 John Heiss, MD,1 Yeshavanth Kumar Banasavadi- Siddegowda, PhD1 1Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA 2University of Miami Miller School of Medicine, Miami, FL, USA *Corresponding Author: Yeshavanth Kumar Banasavadi-Siddegowda, 10 Center Drive, Room 3D03 Bethesda, MD 20892-1414. Phone: 301-451-0970; E-mail: [email protected] Abstract Protein phosphatase 2A (PP2A) is a ubiquitous serine/threonine phosphatase implicated in a wide variety of regulatory cellular functions. PP2A is abundant in the mammalian nervous system and dysregulation of its cellular functions are associated with myriad neurodegenerative disorders. Additionally, PP2A has oncologic implications, recently garnering attention and emerging as a therapeutic target because of the antitumor effects of a potent PP2A inhibitor, LB100. LB100 abrogation of PP2A is believed to exert its inhibitory effects on tumor progression through cellular chemo- and radio-sensitization to adjuvant agents. An updated and unifying review of PP2A biology and inhibition with LB100 as a therapeutic strategy for targeting cancers of the nervous system is needed, as other reviews have mainly covered broader applications of LB100. In this review, we discuss the role of PP2A in normal cells and tumor cells of the nervous system. Further, we summarize current evidence regarding the therapeutic potential of LB100 for treating solid tumors of the nervous system.
    [Show full text]
  • Investigating Developmental and Epileptic Encephalopathy Using Drosophila Melanogaster
    International Journal of Molecular Sciences Review Investigating Developmental and Epileptic Encephalopathy Using Drosophila melanogaster Akari Takai 1 , Masamitsu Yamaguchi 2,3, Hideki Yoshida 2 and Tomohiro Chiyonobu 1,* 1 Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan; [email protected] 2 Department of Applied Biology, Kyoto Institute of Technology, Matsugasaki, Sakyo-ku, Kyoto 603-8585, Japan; [email protected] (M.Y.); [email protected] (H.Y.) 3 Kansai Gakken Laboratory, Kankyo Eisei Yakuhin Co. Ltd., Kyoto 619-0237, Japan * Correspondence: [email protected] Received: 15 August 2020; Accepted: 1 September 2020; Published: 3 September 2020 Abstract: Developmental and epileptic encephalopathies (DEEs) are the spectrum of severe epilepsies characterized by early-onset, refractory seizures occurring in the context of developmental regression or plateauing. Early infantile epileptic encephalopathy (EIEE) is one of the earliest forms of DEE, manifesting as frequent epileptic spasms and characteristic electroencephalogram findings in early infancy. In recent years, next-generation sequencing approaches have identified a number of monogenic determinants underlying DEE. In the case of EIEE, 85 genes have been registered in Online Mendelian Inheritance in Man as causative genes. Model organisms are indispensable tools for understanding the in vivo roles of the newly identified causative genes. In this review, we first present an overview of epilepsy and its genetic etiology, especially focusing on EIEE and then briefly summarize epilepsy research using animal and patient-derived induced pluripotent stem cell (iPSC) models. The Drosophila model, which is characterized by easy gene manipulation, a short generation time, low cost and fewer ethical restrictions when designing experiments, is optimal for understanding the genetics of DEE.
    [Show full text]
  • A Novel Family of DOCK180-Related Proteins 4903
    Research Article 4901 Identification of an evolutionarily conserved superfamily of DOCK180-related proteins with guanine nucleotide exchange activity Jean-François Côté and Kristiina Vuori* The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA *Author for correspondence (e-mail: [email protected]) Accepted 11 October 2002 Journal of Cell Science 115, 4901-4913 © 2002 The Company of Biologists Ltd doi:10.1242/jcs.00219 Summary Mammalian DOCK180 protein and its orthologues DOCK180-mediated Rac activation in vivo. Importantly, Myoblast City (MBC) and CED-5 in Drosophila and we have identified several novel homologues of DOCK180 Caenorhabditis elegans, respectively, function as critical that possess this domain and found that many of them regulators of the small GTPase Rac during several directly bind to and exchange GDP for GTP both in vitro fundamentally important biological processes, such as and in vivo on either Rac or another Rho-family member, cell motility and phagocytosis. The mechanism by which Cdc42. Our studies therefore identify a novel protein DOCK180 and its orthologues regulate Rac has remained domain that interacts with and activates GTPases and elusive. We report here the identification of a domain suggest the presence of an evolutionarily conserved within DOCK180 named DHR-2 (Dock Homology Region- DOCK180-related superfamily of exchange factors. 2) that specifically binds to nucleotide-free Rac and activates Rac in vitro. Our studies further demonstrate that the DHR-2 domain is both necessary and sufficient for Key words: Cytoskeleton, GTPase, Rac, Signaling Introduction (Albert et al., 2000; Cheresh et al., 1999; Dolfi et al., 1998; Mammalian DOCK180 was originally identified as a 180 kDa Gumienny et al., 2001; Kiyokawa et al., 1998a).
    [Show full text]
  • Review of PP2A Tumor Biology and Antitumor Effects of PP2A Inhibitor LB100 in the Nervous System
    cancers Review Review of PP2A Tumor Biology and Antitumor Effects of PP2A Inhibitor LB100 in the Nervous System Jean-Paul Bryant 1 , Adam Levy 2 , John Heiss 1 and Yeshavanth Kumar Banasavadi-Siddegowda 1,* 1 Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA; [email protected] (J.-P.B.); [email protected] (J.H.) 2 Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-301-451-0970 Simple Summary: Central and peripheral nervous system tumors represent a heterogenous group of neoplasms which often demonstrate resistance to treatment. Given that these tumors are often refractory to conventional therapy, novel pharmaceutical regimens are needed for successfully treating this pathology. One such therapeutic is the serine/threonine phosphatase inhibitor, LB100. LB100 is a water-soluble competitive protein phosphtase inhibitor that has demonstrated antitumor effects in preclinical and clinical trials. In this review, we aim to summarize current evidence demonstrating the efficacy of LB100 as an inhibitor of nervous system tumors. Furthermore, we review the involvement of the well-studied phosphatase, protein phosphatase 2A, in oncogenic cell signaling pathways, neurophysiology, and neurodevelopment. Abstract: Protein phosphatase 2A (PP2A) is a ubiquitous serine/threonine phosphatase implicated in a wide variety of regulatory cellular functions. PP2A is abundant in the mammalian nervous system, and dysregulation of its cellular functions is associated with myriad neurodegenerative Citation: Bryant, J.-P.; Levy, A.; disorders. Additionally, PP2A has oncologic implications, recently garnering attention and emerging Heiss, J.; Banasavadi-Siddegowda, as a therapeutic target because of the antitumor effects of a potent PP2A inhibitor, LB100.
    [Show full text]
  • Connective Tissue Disorders
    UNIVERSITY OF MINNESOTA PHYSICIANS OUTREACH LABS Submit this form along with the appropriate Molecular requisition (Molecular Diagnostics or MOLECULAR DIAGNOSTICS (612) 273-8445 Molecular NGS Oncology). DATE: TIME COLLECTED: PCU/CLINIC: AM PM PATIENT IDENTIFICATION DIAGNOSIS (Dx) / DIAGNOSIS CODES (ICD-9) - OUTPATIENTS ONLY SPECIMEN TYPE: o Blood (1) (2) (3) (4) PLEASE COLLECT 5-10CC IN ACD-A OR EDTA TUBE ORDERING PHYSICIAN NAME AND PHONE NUMBER: Tests can be ordered as a full panel, or by individual gene(s). Please contact the genetic counselor with any questions at 612-624-8948 or by pager at 612-899-3291. _______________________________________________ Test Ordered- EPIC: Next generation sequencing(Next Gen) Sunquest: NGS FBN1 Connective tissue Asphyxiating thoracic dystrophy Cranioectodermal dysplasia 2 disorders Full panel WDR35 IFT80 Achondrogenesis DYNC2H1 Craniolenticulosutural dysplasia Full panel TTC21B SEC23A SLC26A2 WDR19 Craniosynostosis TRIP11 Atelosteogenesis Full panel COL2A1 Full panel FGFR2 Achondroplasia SLC26A2 IL11RA FGFR3 FLNB CYP26B1 Acrocapitofemoral dysplasia Brachydactyly TWIST1 IHH Full panel MSX2 Acrodysostosis GDF5 FGFR1 Full panel BMP2 FGFR3 PRKAR1A PTHLH PDE4D Brachyolmia Cutis laxa Acrofacial dysostosis Full panel Full panel Full panel PAPSS2 ATP6V0A2 SF3B4 TRPV4 EFEMP2 DHODH Campomelic dysplasia with autosomal PYCR1 Acromesomelic dysplasia sex reversal ALDH18A1 Full panel SOX9 GDF5 Camurati-Engelmann disease De la Chapelle dysplasia NPR2 TGFB1 SLC26A2 Alport syndrome Cenani-Lenz syndactyly syndrome Full
    [Show full text]